BioSpace News Archive

Kairos Pharma, Ltd. (“Kairos”), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that it has received FDA approval to proceed with a Phase 2 clinical trial of ENV105 with apalutamide for the treatment of metastatic castration-resistant prostate cancer.

Theradaptive, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis, or retrolisthesis.

According to Emergen Research, the global biophotonics market size was USD 54.80 billion in 2020 and is expected to reach USD 132.80 billion in 2028 and register a revenue CAGR of 11.7% during the forecast period, 2021-2028.

RxDefine, the provider of the first digital end-to-end solution for life science commercialization, today announced the hiring of its first General Counsel, Dan Vorhaus, and Director of Compliance, Nicholas Lawrence.

Phototherapy is an effective treatment in which light waves are used to treat various skin conditions such as psoriasis, vitiligo, lichen planus, itchy skin, eczema and cutaneous t-cell lymphoma.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2021.

PacBio announced financial results for the quarter and fiscal year ended December 31, 2021.

Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.

VBL Therapeutics announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective February 13, 2022 of a non-qualified stock option to purchase an aggregate of 300,000 ordinary shares of VBL as an inducement material to Matthew Trudeau entering into employment with VBL in accordance with Nasdaq Listing Rule 5635.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March 1, 2022 , after the close of the U.S. financial markets.